Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629

Abstract Introduction At first interim analysis of KEYNOTE-629, health-related quality of life (HRQoL) with pembrolizumab was stable or improved over 48 weeks in recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC). HRQoL results from the second interim analysis in R/M or locally a...

Full description

Bibliographic Details
Main Authors: Åse Bratland, Eva Munoz-Couselo, Laurent Mortier, Osama Roshdy, Rene González, Jacob Schachter, Ana M. Arance, Florent Grange, Nicolas Meyer, Abhishek Jagdish Joshi, Salem Billan, Brett G. M. Hughes, Jean-Jacques Grob, Karthik Ramakrishnan, Joy Ge, Burak Gumuscu, Ramona F. Swaby, Ralf Gutzmer
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-11-01
Series:Dermatology and Therapy
Subjects:
Advanced squamous cell carcinoma
Immunotherapy
Pembrolizumab
Quality of life
Online Access:https://doi.org/10.1007/s13555-023-01059-y

Internet

https://doi.org/10.1007/s13555-023-01059-y

Similar Items